EICHORPublic-registry trials using Pegloticase that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
Pegloticase appears in 1 registered trial Eichor's radar has found, sponsored by Ampel BioSolutions, LLC, the most recent registered as Phase 2, with a planned enrollment of 132. Registered timeline: 2015–2020. The registry holds 405 registered studies for Gout.
| Trial | Sponsor | Condition | Phase | Sites |
| Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect | Ampel BioSolutions, LLC | Gout | PHASE2 | 11 |
| Status | Completed · planned start 2015-12 |
| Primary completion | 2020-04 |
| Enrollment target | 132 participants |
| Design | Non Randomized · Single Group · Phase 2 · 6 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 11 listed in United States |
All fields verbatim from the ClinicalTrials.gov record for NCT02598596.
| First FDA approval | KRYSTEXXA — September 2010 (application BLA125293, currently held by HORIZON PHARMA) |
| Also known as | KRYSTEXXA |
| Approved applications | 1 |
| Forms & routes | Injectable · Injection |
| Registry-wide use | 23 registered studies all-time · 1 currently recruiting |
Sources: FDA Drugs@FDA and ClinicalTrials.gov, public records. The application holder shown is the current holder, which may differ from the original developer.
The public registry holds 405 registered studies for Gout. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Gout studies · Weekly briefs
